JP2021533766A5 - - Google Patents
Info
- Publication number
- JP2021533766A5 JP2021533766A5 JP2021507552A JP2021507552A JP2021533766A5 JP 2021533766 A5 JP2021533766 A5 JP 2021533766A5 JP 2021507552 A JP2021507552 A JP 2021507552A JP 2021507552 A JP2021507552 A JP 2021507552A JP 2021533766 A5 JP2021533766 A5 JP 2021533766A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr1
- cdr2
- cdr3
- dab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023182454A JP2023178408A (ja) | 2018-08-13 | 2023-10-24 | 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1813178.9 | 2018-08-13 | ||
| GBGB1813178.9A GB201813178D0 (en) | 2018-08-13 | 2018-08-13 | Cell |
| PCT/GB2019/052275 WO2020035676A1 (en) | 2018-08-13 | 2019-08-13 | Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023182454A Division JP2023178408A (ja) | 2018-08-13 | 2023-10-24 | 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533766A JP2021533766A (ja) | 2021-12-09 |
| JP2021533766A5 true JP2021533766A5 (enExample) | 2022-06-02 |
| JP7416762B2 JP7416762B2 (ja) | 2024-01-17 |
Family
ID=63667077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507552A Active JP7416762B2 (ja) | 2018-08-13 | 2019-08-13 | 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞 |
| JP2023182454A Withdrawn JP2023178408A (ja) | 2018-08-13 | 2023-10-24 | 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023182454A Withdrawn JP2023178408A (ja) | 2018-08-13 | 2023-10-24 | 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20230330139A1 (enExample) |
| EP (1) | EP3837284A1 (enExample) |
| JP (2) | JP7416762B2 (enExample) |
| CN (4) | CN118930653A (enExample) |
| AU (3) | AU2019321066B2 (enExample) |
| CA (1) | CA3109752A1 (enExample) |
| GB (1) | GB201813178D0 (enExample) |
| WO (1) | WO2020035676A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7711945B2 (ja) * | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| BR112022016550A2 (pt) * | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
| WO2022099175A1 (en) * | 2020-11-09 | 2022-05-12 | 2Seventy Bio, Inc. | Cd33 targeted immunotherapies |
| CN113248621B (zh) * | 2020-12-11 | 2022-11-04 | 广州百暨基因科技有限公司 | Cll1和cd33双靶点嵌合抗原受体及其应用 |
| CN113045658B (zh) | 2020-12-11 | 2021-12-24 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| CN115197330B (zh) * | 2021-04-14 | 2023-04-28 | 广州百暨基因科技有限公司 | 同时靶向cll1和cd33的嵌合抗原受体及其应用 |
| CN117715935A (zh) * | 2021-07-30 | 2024-03-15 | 南京传奇生物科技有限公司 | 抗cd33抗体及其用途 |
| EP4377353A4 (en) * | 2021-07-30 | 2025-12-17 | Nanjing Legend Biotech Co Ltd | ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOF |
| CN116018351A (zh) * | 2021-08-16 | 2023-04-25 | 上海优替济生生物医药有限公司 | 靶向cd123的抗体、嵌合抗原受体及其用途 |
| CN116063490A (zh) * | 2021-09-07 | 2023-05-05 | 苏州晟济药业有限公司 | 一种vhh抗体或其抗原片段的突变体及其用途 |
| WO2023205876A1 (en) * | 2022-04-29 | 2023-11-02 | Novobind Livestock Therapeutics Inc. | Antibodies against disease causing agents of plants and uses thereof |
| GB202209920D0 (en) | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
| CN116239690B (zh) * | 2022-12-27 | 2024-01-30 | 四川大学 | 一种抗cd123的纳米抗体及其制备方法和应用 |
| CN117482246B (zh) * | 2022-12-30 | 2024-10-15 | 英百瑞(杭州)生物医药有限公司 | 抗cd33/cll1双特异性抗体-自然杀伤细胞偶联物及其用途 |
| CN117964760B (zh) * | 2023-12-21 | 2024-09-03 | 四川大学华西医院 | 抗人cll1/cd3的双特异性抗体及其应用 |
| WO2026015644A1 (en) * | 2024-07-10 | 2026-01-15 | The Trustees Of The University Of Pennsylvania | Cadherin-17 targeting antigen biding polypeptides, chimeric antigen receptors, car-t cells and methods of treating cadherin-17 positive cancers |
| GB202414617D0 (en) | 2024-10-04 | 2024-11-20 | Chancellor Masters And Scholars Of The Univ Of Oxford | Immunotherapy |
| CN122234223A (zh) * | 2026-05-21 | 2026-06-19 | 济南微生态生物医学省实验室 | 一种靶向nk1r的纳米抗体及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| EP3858379A1 (en) | 2013-11-21 | 2021-08-04 | Autolus Limited | Cell |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| BR112017000939A2 (pt) * | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| EP3250602A1 (en) * | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201503133D0 (en) | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| WO2016142532A1 (en) * | 2015-03-11 | 2016-09-15 | Cellectis | Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients |
| GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| TWI833684B (zh) * | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| JP6894430B2 (ja) * | 2015-08-24 | 2021-06-30 | セレクティスＣｅｌｌｅｃｔｉｓ | 統合された制御機能を有するキメラ抗原受容体 |
| GB201518817D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| US20230071283A1 (en) * | 2016-04-15 | 2023-03-09 | Aimee S. Payne | Compositions and methods for selective protein expression |
| GB201607968D0 (en) * | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| PL3896091T3 (pl) * | 2016-08-10 | 2024-04-29 | Legend Biotech Ireland Limited | Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania |
-
2018
- 2018-08-13 GB GBGB1813178.9A patent/GB201813178D0/en not_active Ceased
-
2019
- 2019-08-13 WO PCT/GB2019/052275 patent/WO2020035676A1/en not_active Ceased
- 2019-08-13 CN CN202411248075.1A patent/CN118930653A/zh active Pending
- 2019-08-13 JP JP2021507552A patent/JP7416762B2/ja active Active
- 2019-08-13 CN CN201980053953.5A patent/CN112566941B/zh active Active
- 2019-08-13 US US17/268,328 patent/US20230330139A1/en not_active Abandoned
- 2019-08-13 AU AU2019321066A patent/AU2019321066B2/en active Active
- 2019-08-13 CN CN202411248012.6A patent/CN118878688A/zh active Pending
- 2019-08-13 CN CN202411247931.1A patent/CN118909124A/zh active Pending
- 2019-08-13 EP EP19758458.4A patent/EP3837284A1/en active Pending
- 2019-08-13 CA CA3109752A patent/CA3109752A1/en active Pending
-
2023
- 2023-10-24 JP JP2023182454A patent/JP2023178408A/ja not_active Withdrawn
-
2025
- 2025-01-15 US US19/021,501 patent/US20250381224A1/en active Pending
-
2026
- 2026-04-24 AU AU2026203095A patent/AU2026203095A1/en active Pending
- 2026-04-24 AU AU2026203096A patent/AU2026203096A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106604932B (zh) | 人白细胞介素-2的免疫刺激单克隆抗体 | |
| JP2020525032A5 (enExample) | ||
| CN114502591B (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JP2021514664A5 (enExample) | ||
| JP2021534762A5 (enExample) | ||
| JP2021511811A5 (enExample) | ||
| JP2023526774A5 (enExample) | ||
| JP2020511152A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| EP3289082A1 (en) | Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens | |
| JP2020503870A5 (enExample) | ||
| JP2016196468A5 (enExample) | ||
| JP2021528047A5 (enExample) | ||
| JP2024531409A5 (enExample) | ||
| JP2010511388A5 (enExample) | ||
| JP2014088414A5 (enExample) | ||
| JP2008543339A5 (enExample) | ||
| JP2021524275A5 (enExample) | ||
| JP2022511735A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| WO2021068761A1 (zh) | 靶向bcma的具有人猴交叉的人源化单克隆抗体 | |
| JP2021517459A5 (enExample) | ||
| CN119306837B (zh) | 一种抗cd276的纳米抗体及其应用 | |
| JP2024530325A5 (enExample) | ||
| JP2023507740A5 (enExample) |